FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Louis Misset

Research Profile

Procedures

Chemicals & Drugs

Disorders

Activities & Behaviors

Drug Evaluation

Concepts & Ideas

Co-author Network

Publications

TOP 3
Axel Le Cesne; ROBERT G MAKI; Jean-Louis Misset; Antonio Nieto; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Pilar Frontelo; Juhui James Jiao; George D Demetri
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
David Groheux; Anne-Sophie Hamy; Jean-Louis Misset; Marie-Elisabeth Toubert; Laetitia Vercellino; Nathalie Berenger; Marc Delord; Marc Espié; Sylvie Giacchetti; Elif Hindié
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Anne-Lise Pouliquen; Jean-Louis Misset; C Bauer; G Bousquet; Christine Le Maignan; N Lejri; F Lokiec
Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Louis Misset (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Axel Le Cesne; ROBERT G MAKI; Jean-Louis Misset; Antonio Nieto; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Pilar Frontelo; Juhui James Jiao; George D Demetri
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Investigational new drugs 2012;30(3):1193-202.
2011: David Groheux; Anne-Sophie Hamy; Jean-Louis Misset; Marie-Elisabeth Toubert; Laetitia Vercellino; Nathalie Berenger; Marc Delord; Marc Espié; Sylvie Giacchetti; Elif Hindié
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(10):1526-34.
2011: Anne-Lise Pouliquen; Jean-Louis Misset; C Bauer; G Bousquet; Christine Le Maignan; N Lejri; F Lokiec
Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2011;17(3):265-9.
2010: Tamás Kullmann; Jean-Louis Misset
[Evaluating the benefits of mammographic breast cancer screening].
Orvosi hetilap 2010;151(35):1409-14.
2009: David Groheux; Elif Hindié; Domenico Rubello; Marc Espié; Georges Baillet; Sylvie Giacchetti; Jean-Louis Misset; Jean-Luc Moretti
Should FDG PET/CT be used for the initial staging of breast cancer?
European journal of nuclear medicine and molecular imaging 2009;36(10):1539-42.
2009: Laetitia Vercellino; Guilhem Bousquet; Georges Baillet; Emmanuelle Barré; Olivier Mathieu; Pierre-Alexandre Just; François Desgrandchamps; Jean-Louis Misset; Elif Hindié; Jean-Luc Moretti
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Cancer biotherapy & radiopharmaceuticals 2009;24(1):137-44.
2008: Michel Marty; Jean-Yves Blay; Jean Trédaniel; serge koscielny; Charles Hagège; Bernard Asselain; François Goldwasser; Jean-Louis Misset
[Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)].
Bulletin du cancer 2008;95(11):1075-82.
2008: David Groheux; Jean-Luc Moretti; Georges Baillet; Marc Espie; Sylvie Giacchetti; Elif Hindie; Christophe Hennequin; Jacques-Robert Vilcoq; Caroline Cuvier; Marie-Elisabeth Toubert; Jean-Emmanuel FILMONT; Farid Sarandi; Jean-Louis Misset
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
International journal of radiation oncology, biology, physics 2008;71(3):695-704.
2008: Jean Trédaniel; Francesco Savinelli; Guillaume Sergent; Guilhem Bousquet; Christine Le Maignan; Christophe Hennequin; Dominique Gossot; Jean-Louis Misset
[Lung cancers in the elderly].
Bulletin du cancer 2008;95 FMC Onco():F57-64.
2008: ISABELLE RAY COQUARD; Diana Kassab-Chahmi; Nicole Casadevall; Pascal Chastagner; Christian Marchal; Perrine Marec-Bérard; Jean-Louis Misset
[Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)].
Bulletin du cancer 2008;95(4):433-41.
2008: Christian Marchal; Jean-Louis Misset; Nicole Casadevall; Perrine Marec-Bérard; Pascal Chastagner; Diana Kassab-Chahmi; Isabelle Ray-Coquard
[Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2008;12(2):126-33.
2007: Catherine Lhommé; F Planchamp; F Joly; E Leblanc; N Albin; C Alliot; G Auclerc; M Cappiello; Loïc Chaigneau; R Delva; Nicole Dohollou; C Guillemet; Jean-Louis Misset; ISABELLE RAY COQUARD; H Rhliouch; Emmanuel Touboul; Christophe Tournigand
[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment].
Bulletin du cancer 2007;94(12):1093-106.
2007: Jean-Yves Blay; serge koscielny; Jean Trédaniel; Bernard Asselain; François Goldwasser; Jean-Louis Misset; Cécile de Labareyre; Charles Hagège; Hervé Bismut; Michel Marty
Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).
Critical reviews in oncology/hematology 2007;64(2):106-14.
2007: M Varna; Hany Soliman; Jean-Paul Feugeas; Elisabeth Turpin; D Chapelin; Luc LEGRES; Louis-François Plassa; Anne de Roquancourt; Marc Espié; Jean-Louis Misset; Anne Janin; Hugues de Thé; Philippe Bertheau
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.
British journal of cancer 2007;97(8):1157-64.
2007: Francis Fagnani; Xavier Colin; Patrick Arveux; Bruno Coudert; Jean-Louis Misset
[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Bulletin du cancer 2007;94(7):711-20.
2007: David Groheux; Elif Hindie; Marc Espié; Marie-Elisabeth Toubert; Jean-Louis Misset; Sylvie Giacchetti; Laetitia Vercellino; Jean-Luc Moretti
[Interests and perspectives of PET-CT for breast cancer: review of the literature].
Bulletin du cancer 2007;94(7):658-68.
2007: O Ba; F Almeida; C Fondronnier; M Michalski; Dominique Gossot; F Savinelli; C Le Maignan; Jean-Louis Misset; Jean Trédaniel
[Abdominal pain during the course of lung cancer].
Revue de pneumologie clinique 2007;63(2):100-3.
2007: Philippe Bertheau; Elisabeth Turpin; David S Rickman; Marc Espié; Aurélien de Reyniès; Jean-Paul Feugeas; Louis-François Plassa; Hany Soliman; Mariana Varna; Anne de Roquancourt; Jacqueline Lehmann-Che; Yves Beuzard; Michel Marty; Jean-Louis Misset; Anne Janin; Hugues de Thé
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
PLoS medicine 2007;4(3):e90.
2007: Thibaut Caruba; Paul-Henri Cottu; Isabelle Madelaine-Chambrin; Marc Espié; Jean-Louis Misset; Marine Gross-Goupil
Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
The breast journal 2007;13(2):165-71.
2006: Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Investigational new drugs 2006;24(4):311-9.
2006: Laurent Zelek; Alejandro Yovine; Etienne Brain; Francois Turpin; Abdelkrim Taamma; M Riofrio; Marc Spielmann; José Jimeno; Jean-Louis Misset
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
British journal of cancer 2006;94(11):1610-4.
2006: Thierry André; Daniel Sargent; Josep Tabernero; Michael O'Connell; Marc Buyse; Alberto Sobrero; Jean-Louis Misset; Corrado Boni; Aimery de Gramont
Current issues in adjuvant treatment of stage II colon cancer.
Annals of surgical oncology 2006;13(6):887-98.
2006: Jean Trédaniel; F Savinelli; Stéphane Vignot; G Bousquet; C Le Maignan; Jean-Louis Misset
[The consequences of passive smoking in adults].
Revue des maladies respiratoires 2006;23 Suppl 2():4S67-4S73.
2006: Catherine Guettier; Pierre Validire; Dominique Emilie; Viviane Tricottet; Mylène Sebagh; Aurora Anjo; Jean-Louis Misset; Michel Reynes
Follicular dendritic cell tumor of the mediastinum: expression of fractalkine and SDF-1alpha as mast cell chemoattractants.
Virchows Archiv : an international journal of pathology 2006;448(2):218-22.
2006: Marie Cécile Douard; Mario di Palma; Patricia d'Agostino; Sylvie Chevret; Irène Kriegel; Bruno Falissard; Patrick Thierry; Brigitte George; Laurence Bussières; Jean-Louis Misset
Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2006;14(2):161-6.
2005: Roland Bugat; Jean-Paul Guastalla; Jean-Louis Misset
[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
Bulletin du cancer 2005;92(11):1003-6.
2005: Philippe Bertheau; Florence Lerebours; Nicolas Mounier; Anne de Roquancourt; Marc Espié; Philippe Clot; Jean-Marie Servant; Jean-Louis Misset; Michel Marty; Anne Janin
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer.
Oncology reports 2005;14(2):513-20.
2005: Jean Trédaniel; Jean-Yves Blay; François Goldwasser; Bernard Asselain; serge koscielny; Cécile de Labareyre; Nives Balogh; Hervé Bismut; Jean-Louis Misset; Michel Marty
Decision making process in oncology practice: is the information available and what should it consist of?
Critical reviews in oncology/hematology 2005;54(3):165-70.
2004: Eric Raymond; Carmen Kahatt; Marie-Hélène Rigolet; William Sutherland; François Lokiec; Jérôme Alexandre; Bertrand Tombal; Michael Elman; Michael S Lee; John R MacDonald; Michael Cullen; Jean-Louis Misset; Esteban Cvitkovic
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7566-74.
2004: Catherine Lhommé; ISABELLE RAY COQUARD; Jean-Paul Guastalla; Anne Bataillard; Laurence Thomas; Pascal Bonnier; Daniel Dargent; Nicole Dohollou; Gérard Ganem; Jean-Pierre Lefranc; Jean-Louis Misset; Olivier Rixe; Xavier Tchiknavorian; Christophe Tournigand; Richard Villet; Thomas Bachelot; Pierre Kerbrat; Béatrice Fervers; Jean-Pierre Basuyau; Christine Cohen-Solal-le Nir; Philippe Morice; Pierre Duvillard; Eric Voog
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].
Bulletin du cancer 2004;91(7-8):609-20.
2004: Jean-Louis Misset; E Gamelin; Mario Campone; S Delaloge; J E Latz; Laurence Bozec; Pierre Fumoleau
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1123-9.
2004: Jérôme Alexandre; Eric Raymond; Mahmoud Ould Kaci; Etienne Brain; François Lokiec; Carmen Kahatt; Sandrine Faivre; Alejandro Yovine; François Goldwasser; Sheri L Smith; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3377-85.
2004: Alejandro Yovine; M Riofrio; Jean-Yves Blay; Etienne Brain; Jérôme Alexandre; Carmen Kahatt; Abdelkrim Taamma; José Jimeno; C Martin; Y Salhi; Esteban Cvitkovic; Jean-Louis Misset
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):890-9.
2003: Catalin Mita; Etienne Chatelut; M Bekradda; Patrick Soulié; Pierre Canal; Jean-Louis Misset; Esteban Cvitkovic; Roland Bugat
Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1776-82.
2003: Gérard Ganem; Michèle Tubiana-Hulin; Pierre Fumoleau; Martin Combe; Jean-Louis Misset; Jean-Michel Vannetzel; Thomas Bachelot; L R De Ybarlucea; V Lotz; B Bendahmane; Véronique Dieras
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1623-8.
2003: J P Droz; X Muracciole; N Mottet; Mahmoud Ould-Kaci; Jean-Michel Vannetzel; N Albin; Stéphane Culine; J-M Rodier; Jean-Louis Misset; S Mackenzie; Esteban Cvitkovic; G Benoit
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1291-8.
2003: Jérôme Alexandre; Marine Gross-Goupil; B Falissard; M-L Nguyen; Jean-Marie Gornet; Jean-Louis Misset; François Goldwasser
Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(1):36-41.
2002: John Crown; Véronique Diéras; Manfred Kaufmann; Gunter von Minckwitz; Stan Kaye; Robert Leonard; Michel Marty; Jean-Louis Misset; Bruno Osterwalder; Martine Piccart
Chemotherapy for metastatic breast cancer-report of a European expert panel.
The lancet oncology 2002;3(12):719-27.
2002: Jim Cassidy; Jean-Louis Misset
Oxaliplatin-related side effects: characteristics and management.
Seminars in oncology 2002;29(5 Suppl 15):11-20.
2002: Marine Gross-Goupil; François Lokiec; G Lopez; Jean-Marie Tigaud; A Hasbini; Didier Romain; Jean-Louis Misset; François Goldwasser
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
European journal of cancer (Oxford, England : 1990) 2002;38(14):1888-98.
2002: Jean-Marie Gornet; Eric Savier; François Lokiec; Esteban Cvitkovic; Jean-Louis Misset; François Goldwasser
Exacerbation of oxaliplatin neurosensory toxicity following surgery.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1315-8.
2002: Daniel G Haller; Jean-Louis Misset
Docetaxel in advanced gastric cancer.
Anti-cancer drugs 2002;13(5):451-60.
2002: Laurent Zelek; Paul-Henri Cottu; Michèle Tubiana-Hulin; Jean-Michel Vannetzel; Philippe Chollet; Jean-Louis Misset; N Chouaki; Michel Marty; Erick Gamelin; Stéphane Culine; Véronique Dieras; S Mackenzie; Marc Spielmann
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2551-8.
2002: N Germann; Marine Gross-Goupil; E Wasserman; Jean-François Emile; Jean-Louis Misset; M Reynes; François Goldwasser
The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):632-6.
2002: Jérôme Alexandre; Jean-Marie Tigaud; Marine Gross-Goupil; Jean-Marie Gornet; Didier Romain; Daniel Azoulay; Jean-Louis Misset; François Goldwasser
Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients.
American journal of clinical oncology 2002;25(2):198-203.
2002: Jean-Noël Talbot; Jean-Didier Rain; Michel Meignan; Serge Askienazy; Yvon Grall; Bernard Bok; Jean-Louis Misset
[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
Bulletin du cancer 2002;89(3):313-21.
2002: Jean-Louis Misset
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Seminars in oncology 2002;29(1 Suppl 3):36-9.
2002: Véronique Dieras; Philippe Bougnoux; T Petit; Philippe Chollet; Philippe Beuzeboc; C Borel; F Husseini; A Goupil; Pierre Kerbrat; Jean-Louis Misset; MA Bensmaïne; I Tabah-Fisch; Pierre Pouillart
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):258-66.
2002: Andrew D Seidman; Joyce O'Shaughnessy; Jean-Louis Misset
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
The oncologist 2002;7 Suppl 6():20-8.
2002: I Monnet; Cremoux H de; Patrick Soulié; S Saltiel-Voisin; M Bekradda; JC Saltiel; Etienne Brain; Olivier Rixe; Y Yataghene; Jean-Louis Misset; Esteban Cvitkovic
Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(1):103-7.
2001: Charlotte van Kesteren; R A Mathĵt; Luis López-Lázaro; Esteban Cvitkovic; Abdelkrim Taamma; José Jimeno; Cecilia Guzman; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Jean-Louis Misset; P Vennin; P H Chollet; P Pouillart; P H Laplaige; J L Frobert; D Castera; M Fabro; D Langlois; E Cortesi; V Lucas; E Gamelin; A Laadem; J Otero
Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1411-5.
2001: Francis Lévi; Sylvie Giacchetti; R Zidani; C Brezault-Bonnet; Jean-Marie Tigaud; François Goldwasser; Jean-Louis Misset
Chronotherapy of colorectal cancer metastases.
Hepato-gastroenterology 2001;48(38):320-2.
2001: Abdelkrim Taamma; Jean-Louis Misset; M Riofrio; Cecilia Guzman; Etienne Brain; Luis Lopez-Lazaro; Hilde Rosing; José Jimeno; Esteban Cvitkovic
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1256-65.
2001: Suzette Delaloge; Alejandro Yovine; Abdelkrim Taamma; M Riofrio; Etienne Brain; Eric Raymond; Paul-Henri Cottu; François Goldwasser; José Jimeno; Jean-Louis Misset; Michel Marty; Esteban Cvitkovic
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1248-55.
2000: Suzette Delaloge; A Laadem; Abdelkrim Taamma; N Chouaki; Esteban Cvitkovic; Patricia Pautier; Jean-Louis Misset; C Lhommé
Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer.
American journal of clinical oncology 2000;23(6):569-74.
2000: Charlotte van Kesteren; Esteban Cvitkovic; Abdelkrim Taamma; Luis López-Lázaro; José Jimeno; Cecilia Guzman; R A Math t; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: François Goldwasser; Marine Gross-Goupil; Jean-Marie Tigaud; Mario Di Palma; J Marceau-Suissa; E Wasserman; Alejandro Yovine; Jean-Louis Misset; Esteban Cvitkovic
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(11):1463-70.
2000: Jean-François Emile; Mario Di Palma; M Musset; Mylène Sebagh; ML Auriault; Jean-Louis Misset; Michel Reynès
[Evaluation of the effect of pathology slide review on clinical practice in an oncology center].
Annales de pathologie 2000;20(4):304-7.
2000: Marie-Christine Mormont; J Waterhouse; P Bleuzen; Sylvie Giacchetti; A Jami; A Bogdan; J Lellouch; Jean-Louis Misset; Y Touitou; Francis Lévi
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3038-45.
2000: Jean-Louis Misset; H Bleiberg; W Sutherland; M Bekradda; Esteban Cvitkovic
Oxaliplatin clinical activity: a review.
Critical reviews in oncology/hematology 2000;35(2):75-93.
2000: Jean-Marie Gornet; Daniel Azoulay; F Lévi; Alejandro Yovine; Jean-Louis Misset; François Goldwasser
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Anti-cancer drugs 2000;11(4):263-8.
2000: Jérôme Alexandre; P Bleuzen; Jacques Bonneterre; W Sutherland; Jean-Louis Misset; Jean-Paul Guastalla; Patrice Viens; Sandrine Faivre; A Chahine; M Spielman; A Bensmaïne; Michel Marty; Mondher Mahjoubi; Esteban Cvitkovic
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):562-73.
2000: C Massari; Silvano Brienza; M Rotarski; J Gastiaburu; Jean-Louis Misset; D Cupissol; E Alafaci; H Dutertre-Catella; G Bastian
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Cancer chemotherapy and pharmacology 2000;45(2):157-64.
2000: Sylvie Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; Christian Focan; Philippe Chollet; J F Llory; Y Letourneau; Bruno Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; René Adam; Jean-Louis Misset; Francis Lévi
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):136-47.
1999: Patrick Soulié; C Garrino; MA Bensmaïne; M Bekradda; Etienne Brain; Mario Di Palma; A Goupil; Jean-Louis Misset; Esteban Cvitkovic
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Journal of cancer research and clinical oncology 1999;125(12):707-11.
1999: Jean-Pierre Armand; D Cunningham; Eric Van Cutsem; Jean-Louis Misset; C H Kohne
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Anti-cancer drugs 1999;10 Suppl 1():S5-12.
1999: Jacques Bonneterre; M Spielman; Jean-Paul Guastalla; Michel Marty; P Viens; Philippe Chollet; Henri Roché; P Fumoleau; Louis Mauriac; Hugues Bourgeois; Moïse Namer; J P Bergerat; Jean-Louis Misset; L Trandafir; Mondher Mahjoubi
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
European journal of cancer (Oxford, England : 1990) 1999;35(10):1431-9.
1999: Catherine Lhommé; Pierre Fumoleau; Pierre Fargeot; Y Krakowski; V Dieras; Jean Chauvergne; P Vennin; P Rebattu; H Roche; Jean-Louis Misset; M A Lentz; Martine Van Glabbeke; A Matthieu-Boué; Dominique Mignard; Bernard Chevallier
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3136-42.
1999: E Wasserman; Caroline Cuvier; François Lokiec; François Goldwasser; S Kalla; Dominique Méry-Mignard; M Ouldkaci; A Besmaine; G Dupont-André; Mondher Mahjoubi; Michel Marty; Jean-Louis Misset; Esteban Cvitkovic
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1751-9.
1999: Sylvie Giacchetti; M Itzhaki; G Gruia; René Adam; R Zidani; Francis Kunstlinger; Silvano Brienza; E Alafaci; F Bertheault-Cvitkovic; Claude Jasmin; M Reynes; Henri Bismuth; Jean-Louis Misset; Francis Lévi
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):663-9.
1999: Jean-Louis Misset; Véronique Dieras; G Gruia; Hugues Bourgeois; Esteban Cvitkovic; S Kalla; Laurence Bozec; Philippe Beuzeboc; Claude Jasmin; J P Aussel; A Riva; Nacer Azli; Pierre Pouillart
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):553-60.
1999: J P Thièry; I Blazsek; S Legras; S Marion; Michel Reynes; Aurora Anjo; René Adam; Jean-Louis Misset
Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor.
Hepatology (Baltimore, Md.) 1999;29(5):1406-17.
1999: N Germann; Silvano Brienza; M Rotarski; Jean-François Emile; Mario Di Palma; M Musset; M Reynes; Patrick Soulié; Esteban Cvitkovic; Jean-Louis Misset
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):351-4.
1999: François Goldwasser; X Buthaud; M Gross; P Bleuzen; Esteban Cvitkovic; A Voinea; C Jasmin; Didier Romain; Jean-Louis Misset
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.
Anti-cancer drugs 1999;10(3):263-5.
1999: F Goldwasser; Laurence Bozec; N Zeghari-Squalli; Jean-Louis Misset
Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.
Anti-cancer drugs 1999;10(2):195-201.
1998: Faouzi Saliba; R Hagipantelli; Jean-Louis Misset; Gérard Bastian; Gilles Vassal; Marc Bonnay; P Herait; C Cote; Mondher Mahjoubi; Dominique Mignard; Esteban Cvitkovic
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2745-51.
1998: Esteban Cvitkovic; Michel Marty; E Wasserman; Caroline Cuvier; François Goldwasser; Jean-Louis Misset
Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Journal of the National Cancer Institute 1998;90(13):1016-7.
1998: Laurence Bozec; Philippe Bierling; Patricia Fromont; F Lévi; P Debat; Esteban Cvitkovic; Jean-Louis Misset
Irinotecan-induced immune thrombocytopenia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):453-5.
1998: Jean-Marc Extra; Michel Marty; Silvano Brienza; Jean-Louis Misset
Pharmacokinetics and safety profile of oxaliplatin.
Seminars in oncology 1998;25(2 Suppl 5):13-22.
1997: E Wasserman; Anne Myara; François Lokiec; François Goldwasser; François Trivin; Mondher Mahjoubi; Jean-Louis Misset; Esteban Cvitkovic
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1049-51.
1997: Francis Lévi; R Zidani; Jean-Louis Misset
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Lancet 1997;350(9079):681-6.
1997: Patrick Soulié; L Trandafir; Abdelkrim Taamma; François Lokiec; Etienne Brain; Jean-Pierre Delord; Catalin Mita; Jean-Michel Vannetzel; Esteban Cvitkovic; Jean-Louis Misset
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.
Anti-cancer drugs 1997;8(8):763-6.
1997: Véronique Diéras; Pierre Fumoleau; S Kalla; Jean-Louis Misset; Nacer Azli; Pierre Pouillart
Docetaxel in combination with doxorubicin or vinorelbine.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S20-2.
1997: Patrick Soulié; A Bensmaïne; C Garrino; Philippe Chollet; Etienne Brain; M Fereres; C Jasmin; M Musset; Jean-Louis Misset; Esteban Cvitkovic
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1400-6.
1997: S Faivre; F Goldwasser; P Soulié; Jean-Louis Misset
Paclitaxel (Taxol)-associated junctional tachycardia.
Anti-cancer drugs 1997;8(7):714-6.
1997: Philippe Chollet; Sabine Charrier; Etienne Brain; Hervé Curé; Isabelle Van Praagh; Viviane Feillel; Monique De Latour; Jacques Dauplat; Jean-Louis Misset; Jean-Pierre Ferrière
Clinical and pathological response to primary chemotherapy in operable breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(6):862-6.
1997: Etienne Brain; Catalin Mita; Patrick Soulié; H Errihani; A C Hardy Bessard; M Chaouche; Jérôme Alexandre; Jean-Pierre Delord; Esteban Cvitkovic; C Jasmin; Jean-Louis Misset
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Journal of cancer research and clinical oncology 1997;123(4):227-31.
1997: Etienne Brain; C Garrino; Jean-Louis Misset; I G Carbonero; M Itzhaki; Esteban Cvitkovic; E Goldschmidt; F Burki; C Regensberg; E Pappo; R Hagipantelli; M Musset
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
British journal of cancer 1997;75(9):1360-7.
1996: F Bertheault-Cvitkovic; A Jami; M Ithzaki; P D Brummer; Silvano Brienza; R Adam; F Kunstlinger; H Bismuth; Jean-Louis Misset; Francis Lévi
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):2950-8.
1996: J Chapiro; M D Palma; L Mignot; M P Lemonnier; E Beaumelou; F Coulet; Jean-Louis Misset; Claude Jasmin
[Gene therapy in oncology: applications to lung cancer].
Revue des maladies respiratoires 1996;13(5):467-76.
1996: Véronique Dieras; Pierre Fumoleau; Hugues Bourgeois; Jean-Louis Misset; Nacer Azli; Pierre Pouillart
Taxoids in combination chemotherapy for metastatic breast cancer.
Anti-cancer drugs 1996;7 Suppl 2():47-52.
1996: Véronique Dieras; Bernard Chevallier; P Kerbrat; I Krakowski; H Roche; Jean-Louis Misset; M A Lentz; Nacer Azli; M Murawsky; A Riva; Pierre Pouillart; Pierre Fumoleau
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
British journal of cancer 1996;74(4):650-6.
1996: Pierre Fumoleau; B Chevallier; P Kerbrat; Y Krakowski; Jean-Louis Misset; C Maugard-Louboutin; Véronique Dieras; Nacer Azli; N Bougon; A Riva; H Roche
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):165-71.
1996: I Blazsek; C Farabos; P Quittet; M L Labat; A F Bringuier; B K Triana; D Machover; Michel Reynes; Jean-Louis Misset
Bone marrow stromal cell defects and 1 alpha,25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias.
Cancer detection and prevention 1996;20(1):31-42.
1995: Francis Lévi; S Giacchetti; R Adam; R Zidani; G Metzger; Jean-Louis Misset
Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
European journal of cancer (Oxford, England : 1990) 1995;31A(7-8):1264-70.
1995: X H Liu; I Blazsek; M Comisso; S Legras; S Marion; P Quittet; A Anjo; G S Wang; Jean-Louis Misset
Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):953-63.
1995: I Blazsek; X H Liu; A Anjo; P Quittet; M Comisso; B Kim-Triana; Jean-Louis Misset
The hematon, a morphogenetic functional complex in mammalian bone marrow, involves erythroblastic islands and granulocytic cobblestones.
Experimental hematology 1995;23(4):309-19.
1995: Francis Lévi; A Soussan; R Adam; J P Caussanel; G Metzger; Claude Jasmin; H Bismuth; M Smolensky; Jean-Louis Misset
A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.
The Journal of infusional chemotherapy 1995;5(3 Suppl 1):153-8.
1995: P Deprés-Brummer; F Berthault-Cvitkovic; F Lĕvi; Silvano Brienza; J M Vannetzel; Claude Jasmin; Jean-Louis Misset
Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
The Journal of infusional chemotherapy 1995;5(3 Suppl 1):144-7.
1995: Yvan Touitou; Francis Lévi; A Bogdan; M Benavides; F Bailleul; Jean-Louis Misset
Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors.
Journal of cancer research and clinical oncology 1995;121(3):181-8.
1994: L Bonhomme; G Fredj; E Ecstein; G Maurisson; C Farabos; Jean-Louis Misset; C Jasmin
Treatment of AIDS-associated Kaposi's sarcoma with oral tretinoin.
American journal of hospital pharmacy 1994;51(19):2417-9.
1994: G Metzger; C Massari; M C Etienne; M Comisso; Silvano Brienza; Y Touitou; G Milano; G Bastian; Jean-Louis Misset; Francis Lévi
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Clinical pharmacology and therapeutics 1994;56(2):190-201.
1993: F Bertheault-Cvitkovic; Francis Lévi; S Soussan; Silvano Brienza; R Adam; M Itzhaki; Jean-Louis Misset; H Bismuth
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 1993;29A(13):1851-4.
1993: Francis Lévi; Silvano Brienza; G Metzer; P Deprés-Brummer; F Bertheault-Cvitkovic; R Zidani; R Adam; Jean-Louis Misset
Implications of chronobiology for 5-fluorouracil (5-FU) efficacy.
Advances in experimental medicine and biology 1993;339():169-83.
1992: B Kim-Triana; Jean-Louis Misset; Jean-Claude Madelmont; D Godenèche; M Musset; G Mathé
Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
Anti-cancer drugs 1992;3(3):225-31.
1992: G Fredj; F Dietlin; G Barbier; C Jasmin; L Bonhomme; S Esctein; Jean-Louis Misset; P Meyer; D Kalifa; T Beugre
[Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS].
Thérapie 1992;47(3):245-7.
1992: Francis Lévi; Jean-Louis Misset; Silvano Brienza; R Adam; G Metzger; M Itzakhi; J P Caussanel; F Kunstlinger; S Lecouturier; A Descorps-Declère
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Cancer 1992;69(4):893-900.
1992: I Blazsek; M Musset; D Boulé; M L Labat; M F Bringuier; M Comisso; C Le Maignan; P Ribaud; G Mathé; Jean-Louis Misset
Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25 dihydroxyvitamin D3, and prednisone.
Cancer detection and prevention 1992;16(4):259-64.
1992: G Mathé; Jean-Louis Misset; B K Triana; D Godenèche; Jean-Claude Madelmont; G Meyniel
Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
Drugs under experimental and clinical research 1992;18(4):155-8.
1991: L Bonhomme; G Fredj; S Averous; A M Szekely; E Ecstein; B Trumbic; P Meyer; J M Lang; Jean-Louis Misset; C Jasmin
Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(3):234-5.
1991: Francis Lévi; C Canon; M Dipalma; I Florentin; Jean-Louis Misset
When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery.
Annals of the New York Academy of Sciences 1991;618():312-29.
1991: I Blazsek; C Farabos; M Musset; E Goldschmidt; M Comisso; M Benavides; Z Y Wang; M L Labat; G Mathé; Jean-Louis Misset
Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1991;45(4-5):169-77.
1991: I Blazsek; M Comisso; C Farabos; Jean-Louis Misset
Roles for the heliodynamic hormones, all trans retinoic acid and 1 alpha, 25-dihydroxyvitamin D3, in control of the hematopoietic cell cycle.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1991;45(4-5):157-68.
1991: X H Liu; I Blazsek; J Breard; M Comisso; G Mathe; Jean-Louis Misset
Elliptinium, norcantharidin and tetrachlordecaoxide in combined chemo-immunotherapy prolong the survival of Friend-virus-infected mice.
Drugs under experimental and clinical research 1991;17(9):419-26.
1991: I Blazsek; M Comisso; Jean-Louis Misset
Modulation of bone marrow cell functions in vitro by bestatin (ubenimex).
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1991;45(2-3):81-6.
1990: J P Caussanel; Francis Lévi; Silvano Brienza; Jean-Louis Misset; M Itzhaki; R Adam; G Milano; B Hecquet; G Mathé
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
Journal of the National Cancer Institute 1990;82(12):1046-50.
1990: I Blazsek; Jean-Louis Misset; M Benavides; M Comisso; P Ribaud; G Mathé
Hematon, a multicellular functional unit in normal human bone marrow: structural organization, hemopoietic activity, and its relationship to myelodysplasia and myeloid leukemias.
Experimental hematology 1990;18(4):259-65.
1990: Francis Lévi; M Benavides; C Chevelle; F Le Saunier; F Bailleul; Jean-Louis Misset; C Regensberg; J M Vannetzel; A Reinberg; G Mathé
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(4):705-14.
1990: Claude Jasmin; M A Gil-Delgado; J P Marino; E Ecstein; A Descorps-Declere; Jean-Louis Misset
Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(3):189-93.
1989: G Fredj; F Dietlin; D Fredj; L Schwarzenberg; C Jasmin; P Meyer; Jean-Louis Misset
Tetrahydroaminoacridine in HIV infections. The THA Study Group.
International journal of clinical pharmacology, therapy, and toxicology 1989;27(8):408-10.
1989: G Mathé; Yoko Kidani; M Segiguchi; Masazumi Eriguchi; G Fredj; G Peytavin; Jean-Louis Misset; Silvano Brienza; F de Vassals; E Chenu
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1989;43(4):237-50.
1988: I Blazsek; Jean-Louis Misset; M Comisso; G Mathé
Hematon: a multicellular functional unit in primary hematopoiesis.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1988;42(10):661-8.
1987: D Machover; E Goldschmidt; M Benavides; J Gastiaburu; J M Vandenbulcke; M Delgado; Jean-Louis Misset; G Mathe
[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Pathologie-biologie 1987;35(1):79-86.
1987: D Machover; E Goldschmidt; Philippe Chollet; G Metzger; J Zittoun; M Benavides; J Marquet; J M Vandenbulcke; Jean-Louis Misset; L Schwarzenberg
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
NCI monographs : a publication of the National Cancer Institute 1987;(5):193-8.
1987: D Machover; J Gastiaburu; M Delgado; E Goldschmidt; R Hulhoven; M Benavides; Jean-Pierre Lotz; Jean-Louis Misset; F de Vassal; Haim Tapiero
Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
European journal of haematology. Supplementum 1987;47():33-42.
1987: Jean Gugenheim; C Canon; D Samuel; Faouzi Saliba; G Debotte; Jean-Louis Misset; G Mathe; Henri Bismuth
[Immunologic surveillance of liver transplant patients using monoclonal antibodies against lymphocyte subpopulations].
Néphrologie 1987;8(3):99-101.
1986: Francis Lévi; F Bailleul; Jean-Louis Misset; A Reinberg; G Mathe
Timing of maintenance chemotherapy for childhood acute lymphoblastic leukaemia.
Lancet 1986;1(8490):1160-1.
1986: D Machover; E Goldschmidt; Philippe Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; Jean-Louis Misset; L Schwarzenberg; J B Fourtillan
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(5):685-96.
1986: P Ribaud; J Gouveia; Jean-Louis Misset; G Mathé
Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
Oncology 1986;43(2):78-82.
1986: G Mathé; G Santelli; J Gouveia; G Lemaigre; Jean-Louis Misset; F Gros; J P Homasson; B Kim; M C Sudre; H Gaget
Correlation of bronchial epidermoid metaplasia with level of tobacco consumption in heavy smokers.
Cancer detection and prevention 1986;9(1-2):79-81.
1986: Jean-Louis Misset; G Mathé; G Santelli; J Gouveia; J P Homasson; M C Sudre; H Gaget
Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.
Cancer detection and prevention 1986;9(1-2):167-70.
1986: G Mathé; H Umezawa; S Oka; Jean-Louis Misset; Silvano Brienza; F de Vassal; M Musset; P Ribaud; Haim Tapiero
An oriented phase II trial of THP-adriamycin in breast carcinoma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):376-9.
1986: G Mathé; Yoko Kidani; K Triana; Silvano Brienza; P Ribaud; E Goldschmidt; E Ecstein; R Despax; M Musset; Jean-Louis Misset
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):372-6.
1986: G Mathé; I Blazsek; C Canon; M Gil-Delgado; Jean-Louis Misset
From experimental to clinical attempts in immunorestoration with bestatin and zinc.
Comparative immunology, microbiology and infectious diseases 1986;9(2-3):241-52.
1986: G Mathé; Jean-Louis Misset; M Gil-Delgado; M Musset; P Reizenstein; C Canon
A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patients.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):383-5.
1986: G Mathé; H Umezawa; Jean-Louis Misset; Silvano Brienza; C Canon; M Musset; P Reizenstein
Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):379-82.
1986: I Blazsek; E Goldschmidt; D Machover; Jean-Louis Misset; M Benavides; M Comisso; E Ceresi; C Canon; M L Labat; G Mathé
Excess of lympho-reticular cell complexes in the bone marrow linked to T cell mediated dysmyelopoiesis.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(1):28-32.
1985: D Machover; E Goldschmidt; L Schwarzenberg; J M Vanden-Bulcke; Jean-Louis Misset; Philippe Chollet; G Mathé
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1985;4(5):369-76.
1985: D Mathieu; Jean-Louis Misset; B Chardans; D Machover; E Goldschmidt; L Jacques
[A case of septicemia by a Corynebacterium of the J. K. group].
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1985;39(4):173-6.
1985: Jean-Louis Misset; G Mathé; G Santelli; J Gouvela; J P Homasson; M C Sudre; H Gaget
Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.
Acta vitaminologica et enzymologica 1985;7 Suppl():21-5.
1984: D Machover; J Gastiaburu; M Delgado; E Goldschmidt; R Hulhoven; Jean-Louis Misset; F de Vassal; Haim Tapiero; P Ribaud; L Schwarzenberg
Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Cancer treatment reports 1984;68(6):881-6.
1984: D Machover; H Rappaport; L Schwarzenberg; Jean-Louis Misset; E Goldschmidt; G Lemaigre; T Dorval; F De Vassal; P Ribaud; H Gaget
Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long-term maintenance chemotherapy.
Cancer 1984;53(8):1644-50.
1984: D Machover; J Gastiaburu; M Delgado; E Goldschmidt; R Hulhoven; Jean-Louis Misset; F de Vassal; Haim Tapiero; T Dorval; P Ribaud
Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1984;38(7):328-31.
1984: G Mathé; Jean-Louis Misset; D Machover; L Schwarzenberg; M Timus; Claude Jasmin; P Ribaud; M Musset
[Protocols for the treatment of leukemia and lymphoma: toward escalation or toward reduction of degree?].
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1984;38(1):13-32.
1983: V Georgoulias; Jean-Louis Misset; P Ribaud; D Machover; F De Vassal; T Dorval; M Musset; L Schwarzenberg; P Reizenstein; G Mathe; H Gaget
Doxorubicin, vincristine, bleomycin, cytembena and cisplatin as combination chemotherapy for squamous cell lung cancer.
Anticancer research 1983;3(2):107-10.
1982: D Machover; L Schwarzenberg; E D'Hubert; G Lemaigre; B Caillou; J M Tourani; B Michalski; E Goldschmidt; H Gaget; F De Vassal; Jean-Louis Misset; T Dorval; P Ribaud; Claude Jasmin; M Hayat; H Rappaport; G Mathé
[Treatment of acute myeloid leukemia with a protocol combining intensive induction chemotherapy, early consolidation treatment, splenectomy and long-term maintenance chemotherapy. Preliminary study].
La Nouvelle presse médicale 1982;11(52):3835-9.
1982: D Machover; L Schwarzenberg; E Goldschmidt; J M Tourani; B Michalski; M Hayat; T Dorval; Jean-Louis Misset; Claude Jasmin; R Maral; G Mathé
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
Cancer treatment reports 1982;66(10):1803-7.
1982: D Machover; L Schwarzenberg; E Goldschmidt; J M Tourani; B Michalski; M Hayat; T Dorval; Jean-Louis Misset; C Delouche; D Brochon; J P Fraioli; Claude Jasmin; R Maral; G Mathe
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris 1982;58(33):1873-5.
1982: G Mathe; P Schein; J S MacDonald; J L Imbach; Jean-Louis Misset; F De Vassal; P Ribaud; B Serrou; J Gouveia; M Musset; D Machover; L Schwarzenberg; Claude Jasmin; R de Jager
Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU.
European journal of cancer & clinical oncology 1982;18(8):727-32.
1982: Jean-Louis Misset; G Mathé; J Gastiaburu; A Goutner; T Dorval; J Gouveia; L Schwarzenberg; D Machover; P Ribaud; F de Vassal
[Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1982;36(2):112-6.
1982: G Mathé; R de Jager; R Hulhoven; M Delgado; D Machover; P Ribaud; F de Vassal; M Gil-Delgado; Jean-Louis Misset; J Gouveia; Claude Jasmin; M Hayat; J Gastiaburu; L Schwarzenberg
[Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
La Nouvelle presse médicale 1982;11(1):25-8.
1982: G Mathe; J Gouveia; T Hercend; F Gros; T Dorval; J Hazon; Jean-Louis Misset; L Schwarzenberg; P Ribaud; G Lemaigre; G Santelli; P Reizenstein; J P Homasson; J P Gaillard; M Angebault; J P Bonniot; A Lededente; J Marsac; R Parrot; S Pretet; H Gaget
Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment.
Cancer detection and prevention 1982;5(4):461-6.
1982: Jean-Louis Misset; M A Gil-Delgado; M Delgado; F de Vassal; D Machover; A Goutner; G Mathé
[Results of 2 protocols in the treatment of acute lymphoid leukemia in children, according to prognostic factors].
Revista española de oncología 1982;29(4):785-801.
1982: Jean-Louis Misset; F De Vassal; M Delgado; P Ribaud; M Musset; T Dorval; D Machover; Claude Jasmin; M Hayat; L Schwarzenberg; G Mathe
An intensive care chemo- or chemoimmunotherapy regimen for patients with intermediate and poor-prognosis acute lymphatic leukemia and leukemic lymphoblastic lymphosarcoma: preliminary results with 14-month median follow-up.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1982;80():29-35.
1982: Jean-Louis Misset; G Mathé; J Gastiaburu; A Goutner; T I Dorval; J Gouveia; M Hayat; Claude Jasmin; L Schwarzenberg; D Machover; P Ribaud; F de Vassal; J P Horoszewicz
[Treatment of leukemias and lymphomas with interferons: III. Trial treatment of meningeal localizations of acute leukemia and non-Hodgkin's lymphomas with beta interferon administered by the intrathecal route].
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1982;36(3):167-70.
1982: Jean-Louis Misset; G Mathé; J Gastiaburu; A Goutner; T Dorval; J Gouveia; M Hayat; Claude Jasmin; L Schwarzenburg; D Machover; P Ribaud; F De Vassal; J S Horosezewicz
[Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon].
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1982;36(1):55-9.
1982: Jean-Louis Misset; G Mathé; J Gastiaburu; A Goutner; T Dorval; J Gouveia; M Hayat; Claude Jasmin; L Schwarzenberg; D Machover; P Ribaud; F De Vassal
Treatment of lymphoid neoplasias with interferon. II. Human leucocyte alpha-interferon in chronic lymphatic leukemia (CLL). PHase I-II trial.
Anticancer research 1982;2(1-2):67-9.
1982: Jean-Louis Misset; G Mathé; J Gastiaburu; A Goutner; T Dorval; J Gouveia; M Hayat; Claude Jasmin; L Schwarzenberg; D Machover; P Ribaud; F De Vassal; J S Horoszewicz
Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial.
Anticancer research 1982;2(1-2):63-6.
1980: M Bayssas; J Gouveia; F de Vassal; Jean-Louis Misset; L Schwarzenberg; P Ribaud; M Musset; Claude Jasmin; M Hayat; G Mathé
Vindesine: a new vinca alkaloid.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():91-7.
1980: G Mathé; M A Gil; M Delgado; M Bayssas; J Gouveia; P Ribaud; D Machover; Jean-Louis Misset; F de Vassal; L Schwarzenberg; Claude Jasmin; M Hayat
Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():217-22.